Rhabdomyosarcoma

Stop & Shop Fights Pediatric Cancer with Kick Off of ‘Help Cure Childhood Cancer’ Campaign

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, Hospital, Acute lymphoblastic leukemia, MSK, Bruise, Doctor of Philosophy, MD, The Jimmy Fund, Physician, Malignancy, Friends, Cancer, Parent, Skin, Hope, Stop & Shop, EMPOWER, T-cell acute lymphoblastic leukemia, Dana–Farber Cancer Institute, Radiation, Mouth, Stop, Health, Kidney cancer, Adolescence, COVID-19, Wilms' tumor, Leukemia, Young adult, Patient, Family, Pediatrics, Child, Rhabdomyosarcoma, Estate (law), Research, Cheek

Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.

Key Points: 
  • Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.
  • 100% of proceeds will benefit the two hospitals to assist in their pioneering pediatric cancer treatment and care.
  • The Stop & Shop Pediatric Brain Tumor Clinic at Dana-Farber Cancer Institute is a world-renowned destination for children with malignant and non-malignant brain tumors.
  • “Stop & Shop’s dedication and generous support of pediatric cancer continues to help fund critical research and care,” said Scott Armstrong, MD, PhD, chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.

International Team Led by CHOP Cancer Expert Receives Multimillion Dollar Grant for Childhood Cancer Research from Cancer Grand Challenges

Retrieved on: 
Wednesday, March 6, 2024
Survivor, Oncogene, Ewing sarcoma, Doctor of Philosophy, Neoplasm, Cancer Research UK, Hospital, Neuroblastoma, Child, National Cancer Institute, Medulloblastoma, University, Therapy, KiKa, Protein, CHOP, Survival, Pediatrics, Team, Fibrolamellar hepatocellular carcinoma, Rhabdomyosarcoma, Partnership, Pharmaceutical industry

PHILADELPHIA, March 6, 2024 /PRNewswire/ -- An interdisciplinary, global team of scientists led by Yael Mossé, MD, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia (CHOP), has been selected as one of five research teams from all over the world to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK. Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.

Key Points: 
  • Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.
  • Last year, 176 global teams submitted bold ideas for tackling some of the most pressing challenges in cancer research and care.
  • The National Cancer Institute and Cancer Research UK, the world's leading funders of cancer research, co-founded and launched the Cancer Grand Challenges initiative in 2020.
  • In addition to the Team KOODAC3 award, Team MATCHMAKERS, which includes Dr. Nikolaos G. Sgourakis from CHOP, also received a Cancer Grand Challenges award of up to $25 million.

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Mechanism of action, Trial of the century, AACR, Vomiting, Lung cancer, Drug, Conference, Doctor of Philosophy, Carcinoma, CDK9, Nausea, KRON, Kronos, Learning, Case Western Reserve University, Ewing sarcoma, Washington University School of Medicine, Neoplasm, Sarcoma, Safety, Cancer, Patient, Neutropenia, SAN, Rhabdomyosarcoma, Fatigue, Pharmaceutical industry, Medicine

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the presentation of positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting in Dublin, Ireland. Today’s presentation by Dr. Van Tine of Washington University School of Medicine includes clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Massachusetts in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity. Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.

Key Points: 
  • Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.
  • Today, I shared a case study on one of my sarcoma patients who exhausted all standard therapies as well as multiple experimental treatments.
  • The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).
  • To learn more about the preliminary positive KB-0742 data presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Mass.

Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas

Retrieved on: 
Tuesday, October 31, 2023
Osteosarcoma, Graves' ophthalmopathy, Alveolar rhabdomyosarcoma, Poster, TED, Sarcoma, Cancer, Therapy, Rhabdomyosarcoma, Pharmaceutical industry

LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines with well-established IGF-1R pathway involvement, including pediatric sarcomas.

Key Points: 
  • LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines with well-established IGF-1R pathway involvement, including pediatric sarcomas.
  • These include cancers with known genetic alterations affecting the IGF-1R pathway and/or with high IGF-1R expression such as Ewing’s and related sarcomas, rhabdomyosarcoma, and osteosarcoma.
  • Given these promising results, and the existing clinical data, Lirum is planning new clinical trials with LX-101 in pediatric and adult oncologic indications that carry strong ties to the IGF-1/IGF-1R pathway.
  • In parallel, Lirum is also planning to develop LX-101 in certain autoimmune diseases, such as thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated.

Rhabdomyosarcoma Clinical Trial Analysis Research 2023: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 11, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Clinical trial, News, Clinical, Rhabdomyosarcoma, Trial, Pharmaceutical industry

The "Rhabdomyosarcoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rhabdomyosarcoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • This report provides top line data relating to the clinical trials on Rhabdomyosarcoma.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical Trial Reports are generated using the publisher's proprietary database - Pharma - Clinical trials database.

Lirum Therapeutics Presents Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers

Retrieved on: 
Monday, June 5, 2023
Neuroblastoma, Graves' ophthalmopathy, Rhabdomyosarcoma, Osteosarcoma, Alveolar rhabdomyosarcoma, IC50, Therapy, Sarcoma, News, TED, Cancer, Pharmaceutical industry

LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines of pediatric cancers with well-established IGF-1/IGF-1R pathway involvement.

Key Points: 
  • LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines of pediatric cancers with well-established IGF-1/IGF-1R pathway involvement.
  • These include cancers with known genetic alterations affecting the IGF-1/IGF-1R pathway and/or with high IGF-1R expression such as Ewing’s and related sarcomas, rhabdomyosarcoma, osteosarcoma, and neuroblastoma.
  • The audio poster presentation from the conference is available on the Lirum website (www.lirumtx.com) under the News and Events tab.
  • Given these promising results, and the existing clinical data, Lirum is planning new clinical trials with LX-101 in these indications that carry strong ties to the IGF-1/IGF-1R pathway.

Rhabdomyosarcoma Clinical Trial Analysis Report: Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 18, 2023
Pharmaceutical, Health, Clinical Trials, Clinical trial, Top Country Albums, Rhabdomyosarcoma, Trial, Pharmaceutical industry

The "Rhabdomyosarcoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rhabdomyosarcoma Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The clinical trial report provides an overview of Rhabdomyosarcoma Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Rhabdomyosarcoma.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Run Rich Run: 40 Yards Closer to Helping 400,000 Kids Around the World, St. Jude Patient Runs 4.7 second 40-Yard-Dash to Benefit St. Jude Children’s Research Hospital

Retrieved on: 
Saturday, April 29, 2023
Women, Stem Cells, Other Philanthropy, Sports, Managed Care, Men, Family, Surgery, Consumer, Radiology, Oncology, Children, Entertainment, Baby, Maternity, Hospitals, Celebrity, Football, Philanthropy, Health, Fund Raising, Foundation, Fanconi anemia, Survival rate, NFL, Travel, Housing, Food, University, University of Michigan, Kidney cancer, NCI-designated Cancer Center, ALSAC, League, St. Jude Children's Research Hospital, Cancer, Eye, NFL Network, Hope, Wilms' tumor, National Cancer Institute (Egypt), Multimedia, Athlete, National Cancer Institute, Dream, Patient, Super Bowl, Child, Love, Motivation, National Football League Draft, Hospital, Leukemia, Rhabdomyosarcoma, DSM-IV codes, Jude the Apostle

Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.

Key Points: 
  • Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.
  • View the full release here: https://www.businesswire.com/news/home/20230429005038/en/
    Emmy-nominated NFL Network host Rich Eisen suited up and sprinted for St. Jude Children’s Research Hospital® this week during his annual Run Rich Run event.
  • Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Public Interest Groups, Including Consumer Watchdog, Take On Newsom Administration Over Backtracking On Cleanup Of Radioactivity At Santa Susana Site, Case To Be Heard On Monday

Retrieved on: 
Thursday, April 13, 2023
LLP, Cold War, Climate change litigation and the California Environmental Quality Act, California Department of Toxic Substances Control, Reuters, Radiation, Radioactive decay, Santa Susana Field Laboratory, Rhabdomyosarcoma, Public, DTSC, APA, Radioactive waste, Cancer, CEQA, Administrative Procedure Act (United States), Environmental health, Web browser, Recycling, Massachusetts Department of Public Health, Gap, Committee, Administration, Plant, Public health, Florida Third District Court of Appeal, Soil, DPH, Hearing, Comment, SSFL, United States Court of Appeals for the Armed Forces, Groundwater, Consumer Watchdog, Government, Ewing sarcoma, Social, Leukemia, Appellate court, Void coefficient, Hazardous waste, Rare-earth element, Uranium mining, Publishing, Boeing, Physician, Simi Hills

The case was brought by Physicians for Social Responsibility-Los Angeles, the Southern California Federation of Scientists, Committee to Bridge the Gap, and Consumer Watchdog.

Key Points: 
  • The case was brought by Physicians for Social Responsibility-Los Angeles, the Southern California Federation of Scientists, Committee to Bridge the Gap, and Consumer Watchdog.
  • "The Newsom Administration has back-tracked on its duty to the public and promise of an expedited, safe and complete radioactive cleanup of the Boeing site," said Consumer Watchdog senior staff attorney Pam Pressley.
  • More than 700,000 people live within ten miles of one of the most contaminated and dangerous sites in the state.
  • The final brief of consumer and environmental groups replying to the government agencies was filed in October.

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Retrieved on: 
Tuesday, December 13, 2022
GMP, Clinical trial, Security (finance), Neoplasm, Food, Rhabdomyosarcoma, FDA, Marketing, TME, CT, PRV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, LOS, Regulation, MD, Platform, Disease, Patient, Medical imaging, Pharmaceutical industry

“We are thrilled to accelerate our efforts to bring IMX-110 to patients after scaling-up manufacturing of IMX-110,” said Ilya Rachman, MD PhD, CEO of ImmixBio.

Key Points: 
  • “We are thrilled to accelerate our efforts to bring IMX-110 to patients after scaling-up manufacturing of IMX-110,” said Ilya Rachman, MD PhD, CEO of ImmixBio.
  • PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA.  IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors.
  • We believe ImmixBio’s TME Normalization™ technology severs the lifelines between the tumor and its metabolic and structural support.
  • Learn more at www.immixbio.com
    This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events.